{"preliminary_commentary":{"by_channel":{"x_thread":15,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04984343\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"FORT","nct_id":"NCT04984343","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fort-nct04984343. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FORT","arms":[{"description":"Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.","label":"5 radiation treatments - ARM 1","type":"EXPERIMENTAL"},{"description":"Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.","label":"2 radiation treatments - ARM 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["Viewray Inc.","Progenics Pharmaceuticals, Inc."],"completion_date":{"date":"2026-02-19","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Radiation Therapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-04-23","lead_sponsor":"Weill Medical College of Cornell University","official_title":"Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Change in the number of patient-reported GI symptoms using the Expanded Prostate Cancer Index Composite (EPIC)","timeFrame":"Baseline, 24 months"}],"references":[{"citation":"Wolfe S, Diven MA, Marciscano AE, Zhou XK, Kishan AU, Steinberg ML, Miccio JA, Camilleri P, Nagar H. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). BMC Cancer. 2023 Sep 30;23(1):923. doi: 10.1186/s12885-023-11430-z.","pmid":"37777738","type":"DERIVED"}],"start_date":{"date":"2022-02-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04984343"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fort-nct04984343"}